AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT01085214
- Phase
- PHASE2
- Status
- Completed
Conditions
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Laboratory Biomarker Analysis — OTHERCorrelative studies
- Selumetinib — DRUGAZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
Study Details
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
Key Dates
- Start date
- Mar 31, 2010
- Status verified
- May 2015
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
Study Design
- Enrollment
- 37 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AZD6244 (Selumetinib) TreatmentParticipants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Overall Response Rate [ Time Frame: Up to 2 years ]
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | - |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | - |
| Mark O Hatfield-Warren Grant Magnuson Clinical Center | Bethesda | Maryland | 20892 | - |
| National Institutes of Health | Bethesda | Maryland | 20892 | - |
| Billings Clinic Cancer Center | Billings | Montana | 59107 | - |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | - |
| Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | 37232 | - |
| Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia | 23298 | - |
Find similar trials in Tampa, FL
By research site
Moffitt Cancer Center· Tampa, FLEmory University/Winship Cancer Institute· Atlanta, GAUniversity of Maryland/Greenebaum Cancer Center· Baltimore, MDMark O Hatfield-Warren Grant Magnuson Clinical Center· Bethesda, MDNational Institutes of Health· Bethesda, MDBillings Clinic Cancer Center· Billings, MT
Related Studies
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaPHASE1 · Recruiting · Mayo Clinic · Scottsdale, Arizona
- CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaPHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRecruiting · Roswell Park Cancer Institute · Buffalo, New York